Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class. More than half of regular opioid users report back pain. Rates of opioid prescribing in the US and Canada are two to three times higher than in most European countries.
Semnur’s lead program, SP-102 (SEMDEXA™), is the first non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe chronic radicular pain/sciatica, containing no preservatives, surfactants, solvents, or particulates.
Opioid prescriptions account for up to 60 percent of the chronic pain market and carry a well-known risk of abuse and misuse, underscoring the need for alternative pain therapies without the medical and societal challenges.
THE PHASE 3 C.L.E.A.R. CLINICAL RESEARCH STUDY
was conducted at sites throughout the U.S. The purpose of the Study was to evaluate SP-102 (SEMDEXA™) for the relief of sciatica. SP-102 (SEMDEXA™) is a novel, non-opioid injectable gel formulation intended for the treatment of lumbar radicular pain, commonly known as Sciatica.
